Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Oncotarget

Volumn 1, Issue 7, 2010, Pages 639-650

  Rao, Bhavya ^a   van Leeuwen, Ingeborg M M ^b   Higgins, Maureen ^b   Campbel, Johanna ^b   Thompson, Alastair M ^b   Lane, David P ^b   Lain, Sonia ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANEUGEN; ANTINEOPLASTIC AGENT; AURORA KINASE; DACTINOMYCIN; IMIDAZOLE DERIVATIVE; NUTLIN 3; PIPERAZINE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; TOZASERTIB;

ANEUPLOIDY; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL PROTECTION; CELL STRAIN HCT116; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; EVALUATION; GENE INACTIVATION; GENETICS; HUMAN; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANEUGENS; ANEUPLOIDY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOPROTECTION; DACTINOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE KNOCKOUT TECHNIQUES; GENES, P53; HCT116 CELLS; HUMANS; IMIDAZOLES; NEOPLASMS; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES;

EID: 79956035239     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.198     Document Type: Article

References (0)